ML-IAP Antibody (A-1): sc-166390

ML-IAP Antibody (A-1) is a mouse monoclonal IgG2a antibody that detects ML-IAP in human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). ML-IAP, also known as melanoma inhibitor of apoptosis protein, kidney inhibitor of apoptosis protein (KIAP), livin, or BIRC7, plays a crucial role in the regulation of apoptosis, a process vital for maintaining cellular homeostasis and preventing uncontrolled cell proliferation. ML-IAP is primarily located in the cytoplasm, where ML-IAP interacts with key apoptotic regulators, including caspases and Smac, to modulate apoptotic signaling pathways. ML-IAP′s presence in the cytoplasm is significant because ML-IAP allows for direct inhibition of caspase-9, thereby preventing the activation of downstream apoptotic events. Furthermore, ML-IAP′s interaction with Smac, facilitated by unique N-terminal baculovirus IAP repeats (BIRs), underscores ML-IAP′s importance in apoptosis regulation and highlights ML-IAP′s potential as a therapeutic target in cancer treatment. The gene encoding ML-IAP is located on human chromosome 20q13.3, and ML-IAP expression levels can influence the sensitivity of cancer cells to apoptosis, making ML-IAP a critical focus for research in cancer biology and therapeutic development.

The preferred ML-IAP antibody is ML-IAP Antibody (E-3): sc-393237.